IVX-121 RSV Vaccine Description 2022
IVX-121 is an RSV vaccine candidate that incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-CAV1).
IVX-121 will utilize the application of Vaccine-Like Particles (VLP) technology to the DS-CAV1.
VLPs enable high-density, multivalent display of antigens in a manner that closely resembles viruses, with an important difference. VLPs contain no genetic material, so they are non-infectious and can provide a safer alternative to live-attenuated or inactivated vaccines.
Icosavax focus is developing high impact vaccines against infectious diseases to improve human
IVX-121 is a vaccine candidate for the respiratory syncytial virus (RSV) for older adults
IVX-121 is administered as an intramuscular injection
June 10, 2021 - Icosavax Appoints Thomas J. Russo Chief Financial Officer. Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst covering biotechnology, and in operations and vaccine manufacturing for a large pharma company.
April 7, 2021 - Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
May 13, 2020 - Icosavax’s RSV vaccine, IVX-121, is expected to enter clinical trials in 2021. It uses the stabilized prefusion F antigen DC-Cav1, licensed from the National Institute of Allergy & Infectious Diseases at the National Institutes of Health. Preclinical studies suggest IVX-121 is 10 times more effective than the DS-Cav1 antigen alone at neutralizing RSV.
October 3, 2019 - Icosavax announces $51 Million Dollars Raised For RSV Vaccine Development. Extensive preclinical studies conducted at IPD and Icosavax suggest that IVX-121 could increase the protective immunogenicity of RSV F compared to the DS-Cav1 antigen alone.
IVX-121 Clinical Trial
In a Phase 1 clinical study conducted by NIAID/NIH, DS-Cav1 was shown to induce robust neutralizing antibody titers, higher than titers shown in previous studies with RSV postfusion F vaccine candidates.
Extensive preclinical studies suggest that the VLP display of DS-Cav1 in IVX-121 induces higher and more durable neutralizing antibody titers compared to the DS-Cav1 antigen alone, and presentation of DS-Cav1 on the VLP confers improved stability.
Icosavax plans to advance IVX-121 into clinical studies this year.